Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis Anees Bahji, MD; Callum Stephenson; Richard Tyo, BSocSc, RP; Emily R. Hawken, MSc, PhD; Dallas P. Seitz, MD, PhD JAMA Network Open, 2020, 3, (4), e202370. doi : 10.1001/jamanetworkopen.2020.2370 Abstract IMPORTANCE : Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the prevalence of CWS syndrome has not been well described, nor have the factors potentially associated with CWS. OBJECTIVES : To estimate the prevalence of CWS among individuals with regular or dependent use of [...]
Lire la suiteTerpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors David B. Finlay, Kathleen J. Sircombe, Mhairi Nimick, Callum Jones and Michelle Glass Frontiers in Pharmacology, 2020, Volume 11, Article 359, 1-9. doi : 10.3389/fphar.2020.00359 The entourage effect was a proposed explanation for biological observations that endocannabinoid ligand activities can be modified by other lipids released from cells at the same time. An increasing volume of anecdotal reports and interest in the plant have provoked research into the activity of minor chemical constituents of the plant—including volatile terpenoids such as myrcene, a- and b- pinene, b-caryophyllene, and limonene. However, to [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suiteCannabinoids Rescue Cocaine-Induced Seizures by Restoring Brain Glycine Receptor Dysfunction Guichang Zou, Xin Zuo, Kai Chen, ..., Guangming Huang, Dan Liu, Wei Xiong Cell Reports, 2020, 30, 4209–4219 Doi : 10.1016/j.celrep.2020.02.106 In Brief Zou et al. identify the glycine receptor as a potential therapeutic target for cannabinoids in treating cocaine-induced seizures. The function of extra-synaptic glycine receptors in the prefrontal cortex and hippocampus is impaired by cocaine and rescued by cannabinoids, therefore leading to the therapeutic effects of cannabinoids in treating cocaine-induced seizures. Highlights Cannabinoids alleviate cocaine-induced seizures (CISs) by glycine receptors (GlyRs) Cannabinoid docking reduces hydrogen-bonding interaction between cocaine and GlyRs The prefrontal cortex and hippocampus [...]
Lire la suiteWhat does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms ? A comprehensive review Gabrielle Campbell, Wayne Hall and Suzanne Nielsen International Review of Psychiatry, 2018, 1-16. Doi : 10.1080/09540261.2018.1509842 ABSTRACT Pre-clinical research supports that cannabinoids reduce opioid dose requirements, but few studies have tested this in humans. This review evaluates ecological and epidemiological studies that have been cited as evidence that medical cannabis use may reduce opioid use and opioidrelated harms. Medline and Embase were searched for relevant articles. Data were extracted on study setting, analyses approach, covariates, and outcomes. Eleven ecological and 14 epidemiological [...]
Lire la suiteShort-term effects of cannabis consumption on cognitive performance in medical cannabis patients Phillip Olla, Nicholas Rykulski, Jessica L. Hurtubise, Stephen Bartol, Rachel Foote, Laura Cutler, Kaitlyn Abeare, Nora McVinnie, Alana G. Sabelli, Maurissa Hastings, and Laszlo A. Erdodi Applied Neuropsychology : Adult, 2019, 1-11. Doi : 10.1080/23279095.2019.1681424 ABSTRACT This observational study examined the acute cognitive effects of cannabis. We hypothesized that cognitive performance would be negatively affected by acute cannabis intoxication. Twenty-two medical cannabis patients from Southwestern Ontario completed the study. The majority (n¼13) were male. Mean age was 36.0 years, and mean level of education was 13.7 years. Participants were administered the same brief neurocognitive battery three times during [...]
Lire la suiteEffect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults Anthony N. Nicholson, MD, PhD, Claire Turner, BSc, Barbara M. Stone, PhD, and Philip J. Robson, MDy Journal of Clinical Psychopharmacology, 2004, Volume 24, Number 3, 305-313. Doi : 10.1097/01.jcp.0000125688.05091.8f Abstract : The effects of cannabis extracts on nocturnal sleep, earlymorning performance, memory, and sleepiness were studied in 8 healthy volunteers (4 males, 4 females; 21 to 34 years). The study was double-blind and placebo-controlled with a 4-way crossover design. The 4 treatments were placebo, 15 mg D-9-tetrahydro-cannabinol (THC), 5 mg THC combined with 5 mg cannabidiol (CBD), and 15 mg [...]
Lire la suiteBibliographie Cannabinoïdes et CANCER Docteur Christian SUEUR, GRECC, avril 2020. 1 - Activité anti-tumorale des cannabinoïdes : 2 - 14 2 - Cannabinoïdes et Soins Palliatifs dans les pathologies cancéreuses : 15 - 17 3 - Cannabinoïdes et santé mentale en cancérologie : 18 4 - Cannabinoïdes et douleurs cancéreuses : 19 - 23 5 - Cannabinoïdes et chimiothérapies (nausées et vomissements) : 24 - 25
Lire la suiteBibliographie Cannabis et Cannabinoïdes en Neurologie Docteur Christian SUEUR, GRECC, avril 2020. Cannabinoïdes et Sclérose en Plaque, p 4. Cannabinoïdes et Migraines, p 7. Cannabinoïdes et maladies neurodégénératives, p 8. Cannabinoïdes et Maladie de Parkinson, p 10. Cannabinoïdes et Maladie de Huntington, p 11. Cannabinoïdes et Maladie d’Alzheimer, p 12.
Lire la suiteCannabinoids : the lows and the highs of chemotherapy-induced nausea and vomiting Toni Leigh Mortimer, Tom Mabin & Anna-Mart Engelbrecht Future Oncology, 2019 Doi : 10.2217/fon-2018-0530 Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and -9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Although there are many preclinical and clinical studies on the effects of -9- tetrahydrocannabinol during nausea and vomiting, little is known about the role [...]
Lire la suite